Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Santhera Pharmaceuticals Holding AG    SANN   CH0027148649

SANTHERA PHARMACEUTICALS HOLDING AG (SANN)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
07/11/2018 07/12/2018 07/13/2018 07/16/2018 07/17/2018 Date
17.5(c) 17.48(c) 17.18(c) 16.9(c) 16.7 Last
25 196 21 830 6 703 12 372 5 297 Volume
-1.69% -0.11% -1.72% -1.63% -1.18% Change
More quotes
Financials (CHF)
Sales 2018 29,0 M
EBIT 2018 -26,7 M
Net income 2018 -25,0 M
Finance 2018 26,7 M
Yield 2018 -
Sales 2019 31,3 M
EBIT 2019 -20,8 M
Net income 2019 -9,00 M
Finance 2019 50,3 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 2,95x
EV / Sales2019 1,97x
Capitalization 112 M
More Financials
Company
Santhera Pharmaceuticals Holding AG is a pharmaceutical company.It engages in the development, marketing, and commercialization of pharmaceutical products for the treatment of neuro-ophthalmological, neuromuscular, and pulmonary diseases.It offers its products under the Raxone brands.The company... 
Sector
Pharmaceuticals
Calendar
09/04Earnings Release
More about the company
Surperformance© ratings of Santhera Pharmaceuticals H
Trading Rating : - Investor Rating :
More Ratings
Latest news on SANTHERA PHARMACEUTICALS H
07/10SANTHERA PHARMACEUTICALS : to Present Novel Data Highlighting the Clinical Relev..
AQ
07/05SANTHERA PHARMACEUTICALS : to Present Novel Data Highlighting the Clinical Relev..
GL
06/23SANTHERA PHARMACEUTICALS : UK`s MHRA renews Early Access to Medicines Scheme Sci..
AQ
06/22SANTHERA PHARMACEUTICALS : UK's MHRA renews Early Access to Medicines Scheme Sci..
GL
06/14SANTHERA PHARMACEUTICALS : Submits NDA in South Korea for Raxone for the Treatme..
AQ
06/13SANTHERA PHARMACEUTICALS : Submits NDA in South Korea for Raxone for the Treatme..
AQ
06/12SANTHERA PHARMACEUTICALS : Submits NDA in South Korea for Raxone® for the Treatm..
GL
05/12GLOBAL PRIMARY PROGRESSIVE MULTIPLE : F. Hoffmann-La Roche Ltd.: 9strategy.biz ..
AQ
04/17SANTHERA PHARMACEUTICALS : Shareholders approve all Board Proposals at Today's A..
AQ
04/12SANTHERA PHARMACEUTICALS : Shareholders Approve all Board Proposals at Today's A..
GL
More news
Sector news : Specialty & Advanced Pharmaceuticals
07/16Startup Producing Cell-Grown Meat Raises New Funding
DJ
07/16J&J'S JANSSEN : Credence Trial of Invokana Being Stopped Early for Positive Effi..
DJ
07/16ASTRAZENECA : Swedish Business Appoints New CEO
DJ
07/16Indivior's shares soar 33 percent after U.S. court blocks sale of rival gener..
RE
07/16SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
More sector news : Specialty & Advanced Pharmaceuticals
Latest Tweets
04/12Santhera Pharmaceuticals : Shareholders Approve all Board Proposals at Today'.. 
02/22Santhera Pharmaceuticals : Completes Capital Increase to Settle Obtained Lice.. 
01/29Santhera Pharmaceuticals : Reports Preliminary Key Financial Figures for 2017.. 
01/24Santhera Pharmaceuticals : Anticipates Receiving a Negative CHMP Opinion on A.. 
01/19Santhera Pharmaceuticals : Plans to Announce Regulatory Feedback for Raxone® .. 
More tweets
Qtime:27
News from SeekingAlpha
04/09Mereo BioPharma Proposes Terms For U.S. IPO 
03/27Mereo BioPharma Group Files For U.S. IPO 
2017Interview - Santhera Readies Muscular Dystrophy Push 
2016Duchenne Assets Soar In The Wake Of Exondys 51 Approval 
2016Recent Setbacks Have Duchenne Investors On Edge 
Chart SANTHERA PHARMACEUTICALS H
Duration : Period :
Santhera Pharmaceuticals H Technical Analysis Chart | SANN | CH0027148649 | 4-Traders
Technical analysis trends SANTHERA PHARMACEUTICALS H
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 3
Average target price 32,7  CHF
Spread / Average Target 90%
EPS Revisions
Managers
NameTitle
Thomas Meier Chief Executive Officer & Director
Elmar J. Schnee Chairman
Christoph Rentsch Chief Financial Officer
Kristina Sjöblom Nygren Chief Medical Officer, EVP & Head-Development
Martin Gertsch Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
SANTHERA PHARMACEUTICALS HOLDING AG-52.99%112
ABBVIE-0.48%153 340
MERCK KGAA-4.60%12 930
KYOWA HAKKO KIRIN CO LTD-0.99%11 282
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD97.15%11 237
JAZZ PHARMACEUTICALS PLC29.83%10 609